H Lee1, D Sha2, N R Foster3, Q Shi3, S R Alberts4, T C Smyrk1, F A Sinicrope5. 1. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 2. Department of Oncology, Mayo Clinic, Rochester, USA; Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China. 3. Department of Health Science Research, Mayo Clinic, Rochester, MN, USA; Alliance Statistics and Data Center, Mayo Clinic, Rochester, USA. 4. Department of Oncology, Mayo Clinic, Rochester, USA. 5. Department of Oncology, Mayo Clinic, Rochester, USA. Electronic address: sinicrope.frank@mayo.edu.
Abstract
BACKGROUND: Tumor-infiltrating lymphocytes (TILs), tumor budding, and micropapillary architecture may influence tumor growth and metastatic potential, thereby enhancing prognostic stratification. We analyzed these features and their relative contribution to overall outcome and in low (T1-3 N1) and high (T4 and/or N2) risk groups that are used to inform the duration of adjuvant chemotherapy in patients with resected stage III colon cancers. PATIENTS AND METHODS: Among 1532 patients treated in a phase III adjuvant trial of FOLFOX-based therapy, intraepithelial TIL densities, tumor budding, and micropapillary features were analyzed and quantified in routine histopathological sections with light microscopy. Optimal cut-points were determined in association with disease-free survival (DFS) in training and validation sets. Associations or relative contributions of individual features or combined variables with DFS were determined using multivariable Cox regression models. RESULTS: TILs, tumor budding, and micropapillary features were shown to differ significantly by T, N risk groups and by mismatch repair (MMR) status. Low TILs, high budding, and their combined variable [hazard ratio = 2.07 (95% CI, 1.50% to 2.88%); Padj < 0.0001], but not micropapillary features, were each significantly associated with poorer DFS in a training data set and confirmed in a validation set. TILs were prognostic in proficient mismatch repair (pMMR) and deficient mismatch repair (dMMR) tumors; budding was prognostic only in pMMR tumors. The percentage relative contribution of budding/TILs to DFS was second only to nodal status overall, was second (24.4%) after KRAS in low-risk patients, and was the most important contributor (45.4%) in high-risk patients. CONCLUSIONS: TIL density and tumor budding were each validated as significant prognostic variables and their combined variable provided robust prognostic stratification by T, N risk groups, being the strongest predictor of DFS among high-risk stage III patients. CLINICALTRIALS. GOV IDENTIFIER: NCT00079274.
BACKGROUND: Tumor-infiltrating lymphocytes (TILs), tumor budding, and micropapillary architecture may influence tumor growth and metastatic potential, thereby enhancing prognostic stratification. We analyzed these features and their relative contribution to overall outcome and in low (T1-3 N1) and high (T4 and/or N2) risk groups that are used to inform the duration of adjuvant chemotherapy in patients with resected stage III colon cancers. PATIENTS AND METHODS: Among 1532 patients treated in a phase III adjuvant trial of FOLFOX-based therapy, intraepithelial TIL densities, tumor budding, and micropapillary features were analyzed and quantified in routine histopathological sections with light microscopy. Optimal cut-points were determined in association with disease-free survival (DFS) in training and validation sets. Associations or relative contributions of individual features or combined variables with DFS were determined using multivariable Cox regression models. RESULTS: TILs, tumor budding, and micropapillary features were shown to differ significantly by T, N risk groups and by mismatch repair (MMR) status. Low TILs, high budding, and their combined variable [hazard ratio = 2.07 (95% CI, 1.50% to 2.88%); Padj < 0.0001], but not micropapillary features, were each significantly associated with poorer DFS in a training data set and confirmed in a validation set. TILs were prognostic in proficient mismatch repair (pMMR) and deficient mismatch repair (dMMR) tumors; budding was prognostic only in pMMR tumors. The percentage relative contribution of budding/TILs to DFS was second only to nodal status overall, was second (24.4%) after KRAS in low-risk patients, and was the most important contributor (45.4%) in high-risk patients. CONCLUSIONS: TIL density and tumor budding were each validated as significant prognostic variables and their combined variable provided robust prognostic stratification by T, N risk groups, being the strongest predictor of DFS among high-risk stage III patients. CLINICALTRIALS. GOV IDENTIFIER: NCT00079274.
Authors: Harry H Yoon; David Tougeron; Qian Shi; Steven R Alberts; Michelle R Mahoney; Garth D Nelson; Suresh G Nair; Stephen N Thibodeau; Richard M Goldberg; Daniel J Sargent; Frank A Sinicrope Journal: Clin Cancer Res Date: 2014-03-31 Impact factor: 12.531
Authors: Axel Grothey; Alberto F Sobrero; Anthony F Shields; Takayuki Yoshino; James Paul; Julien Taieb; John Souglakos; Qian Shi; Rachel Kerr; Roberto Labianca; Jeffrey A Meyerhardt; Dewi Vernerey; Takeharu Yamanaka; Ioannis Boukovinas; Jeffrey P Meyers; Lindsay A Renfro; Donna Niedzwiecki; Toshiaki Watanabe; Valter Torri; Mark Saunders; Daniel J Sargent; Thierry Andre; Timothy Iveson Journal: N Engl J Med Date: 2018-03-29 Impact factor: 91.245
Authors: Harry H Yoon; Qian Shi; Erica N Heying; Andrea Muranyi; Joerg Bredno; Faith Ough; Azita Djalilvand; June Clements; Rebecca Bowermaster; Wen-Wei Liu; Michael Barnes; Steven R Alberts; Kandavel Shanmugam; Frank A Sinicrope Journal: Clin Cancer Res Date: 2018-10-09 Impact factor: 12.531
Authors: Aziz Zaanan; Qian Shi; Julien Taieb; Steven R Alberts; Jeffrey P Meyers; Thomas C Smyrk; Catherine Julie; Ayman Zawadi; Josep Tabernero; Enrico Mini; Richard M Goldberg; Gunnar Folprecht; Jean Luc Van Laethem; Karine Le Malicot; Daniel J Sargent; Pierre Laurent-Puig; Frank A Sinicrope Journal: JAMA Oncol Date: 2018-03-01 Impact factor: 31.777
Authors: Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar Journal: Nat Med Date: 2015-10-12 Impact factor: 53.440
Authors: Anne Trinh; Claudia Lädrach; Heather E Dawson; Sanne Ten Hoorn; Peter J K Kuppen; Marlies S Reimers; Miriam Koopman; Cornelis J A Punt; Alessandro Lugli; Louis Vermeulen; Inti Zlobec Journal: Br J Cancer Date: 2018-11-02 Impact factor: 7.640
Authors: Frank A Sinicrope; Qian Shi; Aurelie Catteau; Graham M Poage; Tyler J Zemla; Bernhard Mlecnik; Al B Benson; Sharlene Gill; Richard M Goldberg; Morton S Kahlenberg; Suresh G Nair; Anthony F Shields; Thomas C Smyrk; Jerome Galon; Steven R Alberts Journal: JCO Precis Oncol Date: 2022-08
Authors: Jonathan B Yuval; Jasme Lee; Fan Wu; Hannah M Thompson; Floris S Verheij; Hersh V Gupta; Takeshi Irie; Joseph R Scarpa; Patrick J McCormick; J Joshua Smith; Jinru Shia; Martin R Weiser; Francisco Sánchez-Vega; Kay See Tan; Gregory W Fischer; Julio Garcia-Aguilar; Joshua S Mincer Journal: Br J Anaesth Date: 2022-06-17 Impact factor: 11.719
Authors: Dan Sha; Zhaohui Jin; Jan Budczies; Klaus Kluck; Albrecht Stenzinger; Frank A Sinicrope Journal: Cancer Discov Date: 2020-11-02 Impact factor: 38.272
Authors: Sara Sf Al-Badran; Lauren Grant; Maejoy V Campo; Jitwadee Inthagard; Kathryn Pennel; Jean Quinn; Prakash Konanahalli; Liam Hayman; Paul G Horgan; Donald C McMillan; Campbell Sd Roxburgh; Antonia Roseweir; James H Park; Joanne Edwards Journal: J Pathol Clin Res Date: 2020-12-18
Authors: Frank A Sinicrope; Qian Shi; Thomas C Smyrk; Richard M Goldberg; Steven J Cohen; Sharlene Gill; Morton S Kahlenberg; Suresh Nair; Anthony F Shield; Balkrishna N Jahagirdar; Sawyer B Jacobson; Nathan R Foster; Michael N Pollak; Steven R Alberts Journal: JNCI Cancer Spectr Date: 2021-07-23
Authors: Kenji Fujiyoshi; Juha P Väyrynen; Jennifer Borowsky; David J Papke; Kota Arima; Koichiro Haruki; Junko Kishikawa; Naohiko Akimoto; Tomotaka Ugai; Mai Chan Lau; Simeng Gu; Shanshan Shi; Melissa Zhao; Annacarolina Fabiana Lucia Da Silva; Tyler S Twombly; Hongmei Nan; Jeffrey A Meyerhardt; Mingyang Song; Xuehong Zhang; Kana Wu; Andrew T Chan; Charles S Fuchs; Jochen K Lennerz; Marios Giannakis; Jonathan A Nowak; Shuji Ogino Journal: EBioMedicine Date: 2020-07-08 Impact factor: 8.143